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Summary
The mechanistic relationship between amyloid b1-42 (Ab1-42) and
the alteration of Tau protein are debated. We investigated the
effect of Ab1-42 monomers and oligomers on Tau, using mice
expressing wild-type human Tau that do not spontaneously
develop Tau pathology. After intraventricular injection of Ab1-
42, mice were sacrificed after 3 h or 4 days. The short-lasting
treatment with Ab monomers, but not oligomers, showed a
conformational PHF-like change of Tau, together with hyperphos-
phorylation. The same treatment induced increase in concentra-
tion of GSK3 and MAP kinases. The inhibition of the kinases
rescued the Tau changes. Ab monomers increased the levels of
total Tau, through the inhibition of proteasomal degradation. Ab
oligomers reproduced all the aforementioned alterations only
after 4 days of treatment. It is known thatAb1-42monomers foster
synaptic activity. Our results suggest that Ab monomers physio-
logically favor Tau activity and dendritic sprouting, whereas their
excess causes Tau pathology. Moreover, our study indicates that
anti-Ab therapies should be targeted to Ab1-42 monomers too.
Key words: Alzheimer’s disease; beta-amyloid; hTau mice;
MAPK; PHF; tau protein.
Introduction
A series of clues indicate that in Alzheimer’s disease (AD), the
accumulation of amyloid b (Ab) in the brain is the primary and early
event that induces neuronal degeneration, characterized by accumula-
tion of conformational altered and aggregated Tau protein.
Ab derives from the amyloid precursor protein through b site APP
cleaving enzyme 1 (BACE1) and c-secretase processing that generates
multiple C-termini, most ending at residue 40 and 42. Ab1-42
aggregates more quickly and stably than Ab1-40. Ab1-42 polymerization
is believed to occur in sequential phases: First Ab monomers aggregate
into soluble oligomers that then form insoluble oligomers, generating
protofibrils and fibrils (Hubin et al., 2014). Soluble Ab1-42 oligomers
constitute the more toxic form of the peptide (Bolmont et al., 2007;
Nimmrich & Ebert, 2009; Guglielmotto et al., 2014). Monomers have
been proposed to be involved, preferentially, in physiologic processes
(Puzzo et al., 2011; Piccini et al., 2012).
How Ab mediates alteration and aggregation of Tau is uncertain,
although three major mechanisms have been proposed: (i) Ab activates
kinases that phosphorylate Tau (Hernandez & Avila, 2010; Llorens-Martın
et al., 2014) altering its capacity to bind tubulin; (ii) Ab alters the
proteasomal degradation of Tau, increasing its concentration in free state
(Oddo et al., 2009); (iii) Ab intracellular aggregates have a nucleation
effect on Tau (Guo et al., 2006; Bolmont et al., 2007). The third
hypothesis is supported by the occurrence of Tau pathology in different
types of cerebral amyloidosis (Holton et al., 2001; Giaccone et al., 2008).
In this work, given the relevance of soluble monomeric as well as
oligomeric state of Ab1-42 in AD pathogenesis, we studied their role in
altering the aggregation and conformation of Tau protein when injected
inmicewith a pure human Tau (hTau) background (Andorfer et al., 2003).
Results
We performed all experiments injecting 1 lL Ab1-42, monomers and
oligomers, 0.2 lM, in 2-month-old hTau mice, sacrificed after 3 h and
4 days. The results are the average of four identical experiments. The
two preparations were controlled with atomic force microscopy. Peptide
was analyzed immediately after switching and after incubation for 24 h
at 4 °C. Scanning Probe Image Processor (SPIP) software was used to
analyze the distribution of species in terms of heights (Fig. 1C) and
diameters (Fig. 1D). This software enables the elaboration of atomic
force microscopy (AFM) images, and it specifically takes into account the
features of the tips and the tapping mode. Therefore, it is able to obtain
very accurate data on the height and diameter of the molecular
assemblies formed by Ab peptides (Munz, 2013). Figure 1A,B show AFM
images obtained at the initial or oligomeric state of Ab1-42, respectively.
The analysis of the sample at the initial state showed a presence of
assemblies, ranging from 0.2 to 0.5 nm in height (Fig. 1C, blue bars).
The incubation for 24 h at 4 °C leads to the presence of oligomers with
a more broad distribution in height ranging from 0.5 to 2.0 nm (Fig. 1C,
red bars) and the appearance of two families in the range 10–25 nm
(85%) and 40–60 nm (15%) in diameter (Fig. 1D).
Ab1-42 monomers, but not oligomers, induce conformational
change of Tau protein
To determine whether Ab1-42 monomers and oligomers affect Tau
conformation, we performed Western blot analysis using the antibody
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MC1. MC1 is a conformation-dependent antibody that recognizes an
early pathological Tau conformation (Weaver et al., 2000). As showed in
Fig. 1E, 0.2 lM Ab1-42 monomers after 3 h induced Tau protein
conformational change as revealed by the significant increase of the
corresponding band (3.5-fold increase). Monomers are also able to
mediate a significant (twofold) increase of total Tau (Fig. 1E). Oligomeric
forms of Ab1-42 do not modify these parameters (Fig. 1E). We
normalized the levels of bands obtained with MC1 antibody not only
with GAPDH but also with total Tau levels. We found that the
conformational change of Tau is significant after normalization of the
bands with GADPH antibody (2.5-fold) and remains slightly significant
after normalization with total Tau (1.6-fold). Because the conformational
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Fig. 1 Ab1-42 monomers induce a conformational change of Tau protein. (A-B) Analysis of the molecular assemblies of monomeric and oligomeric forms of Ab 1-42. (C)
Representative atomic force microscopy (AFM) images of monomeric (initial state) and oligomeric assemblies, respectively. (D) Histogram representation of the heights of
monomeric (blue bars) and oligomeric (red bars) assemblies, respectively. Distribution of the diameter histogram of oligomeric assemblies. (E) Representative Western blot of
brain extracts from control (saline) and treated (Ab1-42 peptides by ICV for 3 h) mice (2-month-old) using a conformational Tau antibody (MC1) and a total Tau antibody
(Tau5) for detection. An antibody raised against GAPDH or Tau 5 served as loading control. Densitometric quantification shows an increase of the total protein level of both
MC1 and Tau5 induced by monomers. (F) Quantitative real-time PCR (qPCR) analysis on total RNA extracted from brains of control and treated mice. Both treatments were
not able to affect gene transcription. GAPDH mRNA expression was used as the internal standard. (G) Proteasomal activity assay on brain extracts from control and treated
mice. Monomers halved the proteasomal activity. Lactacystin was used as a positive control. (H) Representative Western blot of brain extracts from control (saline) and
treated with Ab1-42 monomeric as well as oligomeric depsipeptides by ICV for 3 h) mice (2-month-old) using a conformational Tau antibody (MC1). An antibody raised
against GAPDH served as loading control. Densitometric quantification shows an increase of the total protein level of both MC1 induced by depsi-monomers. The data are
mean  standard error of the mean (SEM), *P < 0.05; **P < 0.01 vs. control by one-way ANOVA followed by Bonferroni post hoc test, n = 6.
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change recognized by MC1 is found in PHF, but not in normal brain, it
has been suggested that the formation of the MC1 epitope is one of the
earliest pathological alterations of Tau in AD (Weaver et al., 2000). For
this reason, we presumed that the effect mediated by Ab142 monomers
on conformation of Tau is not invalidated by the increase of total Tau.
Next, we investigated whether the increase of total Tau, shown after
treatment with monomers, was due to increased expression of the
protein or to inhibition of its degradation. We found that the injection of
mice with both preparations of Ab1-42 did not increase mRNA levels of
Tau, evaluated with quantitative real-time PCR (qPCR) (Fig. 1F). Thus, we
evaluated whether monomeric preparations were able to alter the
proteasomal degradation of Tau, thus increasing its concentration in free
state. As reported in Fig. 1G, the injection with monomers of Ab1-42
halved the proteasomal activity, in comparison with control animals as
well as to mice injected with oligomers. As positive control, we used
lactacystin, a streptomyces metabolite, which inhibits the proteasomal
degradation of proteins targeting the 20S proteasome (Koh et al.,
2005), to test the validity of the kit. As shown, lactacystin decreased
proteasomal activity by approximately 70%.
For a further confirmation of the results, we used 1 lL of 0.2 lM of
‘depsi’ Ab1-42. This is a new synthetic strategy (‘depsipeptide’
technique) that allows to obtain reliable seed-free solutions of
monomers as well as oligomers of Ab1-42 (Beeg et al., 2011; Stravalaci
et al., 2011). Again, the monomers represent the only preparation
capable of inducing conformational change of the Tau protein, as
revealed by MC1 conformational antibody (Fig. 1H).
Then, we better characterized the conformational change mediated
by Ab1-42 preparations on Tau protein. First, we investigated whether
Ab1-42 preparations changed the levels of three-repeat (RD3) and/or
four-repeat (RD4) Tau in hTau mice. We showed that monomeric
preparations of Ab1-42 were able to slightly but significantly (twofold)
increase the levels of 4R Tau over 3R Tau (Fig. 2A). Oligomers did not
affect these parameters (Fig. 2A).
Then, we studied the insoluble Tau fraction by sarkosyl detergent
technique, and we showed that only after treatment with monomeric
preparations was present a band at approximately 75 kDa molecular
weight revealed by Tau 46 antibody (Fig. 2B).
Ab1-42 monomers induce hyperphosphorylation of Tau
protein
To determine whether Ab1-42 monomers and oligomers modify
phosphorylation of Tau protein, we measured levels of phosphorylation
using AT8 antibody that recognizes Ser202/Thr205 phospho-epitopes.
We performed a pilot experiment to evaluate, by fluorescence,
whether our treatment (Ab1-42 peptides by ICV for 3 h) affected Tau
phosphorylation. Sections from hippocampus were immunostained with
Tau monoclonal antibody AT8. We observed immunoreactivity in the
perinuclear region, primarily in the CA1 pyramidal layer (Fig. 2 Cc0–c″,
d0–d″, e0–e″). Phospho-Tau reactivity was evaluated by IMAGEJ software
and resulted statistically significant in animals injected with monomeric
preparations (Fig. 2 Cb) compared to those treated with oligomers or
control (one-way ANOVA, P < 0.05 vs. oligo, P < 0.01 vs. ctr) (Fig. 2Cb,
d0–d″, e0–e″).
To confirm the results obtained with immunofluorescence, we
measured the levels of hyperphosphorylated Tau using AT8 antibody
in Western blot. Ab1-42 monomers significantly (1.8-fold) increased
hyperphosphorylation of Tau, whereas oligomers did not modify the
parameter (Fig. 3). We confirmed this result normalizing the amount of
phosphorylation with the levels of total Tau, revealed by antibody Tau5,
and we found that the increase of Tau phosphorylation remains slightly
significant also after normalization with total Tau (Fig. 3). Whether Tau
hyperphosphorylation in AD is a cause of aggregation (Alonso et al.,
2001) or whether the two changes occur independently is still
controversial. We tested the ability of Ab1-42 monomers and oligomers
to promote phosphorylation at other particular sites that have been
related to AD progression. Thus, we determined the residues affected by
the injection of Ab1-42 monomers and oligomers using phosphoryla-
tion-sensitive antibodies, such as Tau S396, S422, and S262. As reported
in Fig. 3, the oligomers of Ab1-42 did not induce phosphorylation in the
studied sites. Monomers determined a 1.5-fold and 1.3-fold increase in
phosphorylation of Tau at S396 respective to GADPH or Tau 5
normalization (Fig. 3); the residue S262 was not hyperphosphorylated
if normalized on GADPH or total Tau levels (Fig. 3). The lack of
phosphorylation at this site is not in agreement with literature data
reporting that levels of Ser262 phosphorylation were increased by Ab1-
42, but in those studies were not used Ab monomers (Qureshi et al.,
2013; Ando et al., 2016). The more significant data are the 3.5-fold and
2.8-fold increase of Tau phosphorylation at position S422 with respect to
GAPH or Tau normalization (Fig. 3).
Previous studies reported that Tau is phosphorylated at the afore-
mentioned sites by phospho-kinases such as GSK3b, mitogen-activated
protein kinase (MAPK), and cyclin-dependent kinase (CDK)5 (Fontaine
et al., 2015). Thus, we tested the increase in the concentration of these
kinases in our experimental model 3 h after injection of monomers and
oligomers of Ab1-42 in hTau mice. First, we studied GSK3b, the major
protein kinase regulating Tau phosphorylation in the brain (Hernandez
et al., 2013). We found that injection of Ab1-42 monomers was
followed by an increase (twofold) of pGSK3b protein levels (Fig. 4A)
Then, we tested the levels of CDK5 a protein serine/threonine kinase
(Wilkaniec et al., 2016). As reported in Fig. 4B, levels of CDK5/p35 were
unmodified by injection of monomeric preparations; thus, in our
experimental model, this kinase does not seem involved in the
conformational change of Tau. Finally, we measured levels of MAPK
such as p38, ERK1/2, and JNK. As reported in Fig. 4C, injection of hTau
mice with monomeric preparations was followed by an activation of the
JNK pathway, as shown by significant increase (twofold) in levels of
phospho-JNK. In addition, monomers of Ab1-42 also induced a
significant increase (3.5-fold) of pERK1/2 protein levels without affecting
p38 pathway (Fig. 4C). Oligomers did not activate the three kinases
(Fig. 4A–C).
The mechanisms by which the self-assembly of Ab1-42 leads to
toxicity are not well understood as all intermediated aggregates are
transient and in dynamic balance (Kaden et al., 2012). Thus, we studied
whether a longer treatment of hTau mice, with both oligomeric as well
as monomeric preparations of Ab1-42, would mediate different effects
on Tau. Mice were injected ICV with 1 lL 0.2 lM monomeric as well as
oligomeric Ab1-42 and sacrificed 4 days later. We found that the longer
treatment with oligomers induced effects that mimic those observed
with monomers. As reported in Fig. 5A, we found that oligomers
significantly increase (threefold) the aberrant conformation of Tau as
revealed by MC1 conformational antibody, as well as the amount of
total Tau (twofold increase). Monomers maintain the ability to modify
the conformation and the amount of Tau at the same levels of the
shorter treatment. We also tested the increase in concentration of
GSK3b, pERK1/2, and pJNK to confirm the ability of oligomers to modify
the signal pathways activated after 3 h treatment with monomers of
Ab1-42.
As expected, after 4 days of treatment, oligomeric preparation was
able, as much as monomers, to activate both MAPK kinases, ERK1/2 and
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Fig. 2 Ab1-42 monomers produce alternative splicing, insoluble Tau aggregates, and hyperphosphorylation of Tau protein. (A) Representative Western blot of brain extracts
from control (saline) and treated (Ab1-42 peptides by ICV for 3 h) mice (2-month-old) using a 4-repeat Tau isoform RD4 and 3-repeat Tau isoform RD3 for detection. An
antibody raised against GAPDH served as loading control. Densitometric quantification shows an increase of the isoform with four binding domains mediated by monomers.
(B) Representative Western blot of insoluble Tau fraction by sarkosyl detergent technique extracts from control (saline) and treated (Ab1-42 peptides by ICV for 3 h) mice (2-
month-old) using a Tau 46 antibody for detection. An antibody raised against GAPDH served as loading control. Only after treatment with monomeric preparations was
present a band at approximately 75 kDa molecular weight. (C) a. Schematic image of the mouse hippocampus CA1 region (coronal section). b. Quantification of AT8-
immunoreactive (IR) cells by IMAGEJ NIH software. The data are mean  standard error of the mean (SEM),**P < 0.01 vs. ctr and #P < 0.05 vs. oligo by one-way ANOVA
followed by Bonferroni post hoc test; n = 9. c–e″. Higher magnifications of the box area in a. showing pyramidal layer of control and treated mice (Ab1-42 peptides by ICV
for 3 h) stained with an antibody that recognizes PHF-Tau (AT8 in red). Nuclei are counterstained with DAPI (blue). Scale bars: 100 lm in a, 20 lm in c–e″.
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JNK, and GSK3b pathways as shown by the significant increase (approx.
threefold) in levels of phosphorylation of ERK 1/2, JNK, and pGSK3b
(Fig. 5B). The different effect of oligomeric preparation on Tau confor-
mation after longer treatment could be ascribed to their poor diffusibility
in the brain after 3 h. But, it has been reported that large oligomers of
Ab1-42 after 6 h are clearly able to enter N2A cells (Manzoni et al.,
2011). An alternative hypothesis could be that after 4 days, Ab
oligomers break into smaller aggregates. We tested this hypothesis by
immunoblotting brain tissue of hTau mice injected after 3 h or 4 days
with both preparations (Fig. 5C) with the 6E10 antibody, specific for the
1-16 residues of Ab. As shown, in tissues of mice injected with
monomers after 3 h or 4 days, a band of approx. 8 kDa was observed.
The aggregation state of oligomeric preparation was different in the
short and longer treatments: After 3 h, two bands of approximately 12
and 8 kDA were observed, whereas after 4 days, the higher band was
no longer detectable, and the aggregation state became almost
completely similar to the monomeric form (Fig. 5C). We cannot observe
with this experiment a band of 4 kDa (monomers), because the amount
of beta-amyloid administered is well below the sensitivity of the method.
The phosphorylation of Tau mediated by Ab1-42 monomers is
crucial to mediate the conformational change
Finally, we studied whether an increase in concentration of phospho-
kinases was needed for the conformational change of Tau induced by
Ab1-42 monomers. To investigate whether GSK3b was involved in
conformational change and aggregation of Tau, the GSK3b inhibitor
AZD1080 was given via oral gavage 6 h before the injection of mice with
monomeric preparation of Ab1-42. As reported in Fig. 6A, the
pretreatment with GSK3b inhibitor was able to rescue the increase of
the pathway and to reverse the conformational change of Tau.
To inhibit MAPK, ERK1/2, and JNK, we used PD98059 and SP600125,
respectively, injected ICV 30 min before monomeric preparation of Ab1-
42. Also in this case, we found that the pretreatment was followed by a
complete inhibition of the pathways and by the complete reversion of
Tau conformational change (Fig. 6B,C).
Discussion
This study’s purpose was to investigate whether and how Ab1-42
modifies the conformation of Tau to render it prone to aggregate, in a
PHF-like state. We used a mouse model that expresses wild-type human
Tau and does not spontaneously produce Tau aggregates. In previous
reports, the capability of Ab1-42 to induce Tau aggregation was
studied in mice expressing mutant human Tau, models of tauopathies
(Lewis et al., 2001; Oddo et al., 2006; Rhein et al., 2009; Nisbet et al.,
2015).
We tested the effect on Tau of either oligomers or monomers of Ab1-
42. Ab oligomers lower neuronal activity, through various mechanisms
(Bero et al., 2011; Brouillette et al., 2012; Pitt et al., 2013; Tu et al.,
2014; Xu et al., 2014; Lazzari et al., 2015). Instead, Ab monomers
enhance various cellular functions (Giuffrida et al., 2010). We previously
showed that they increase receptor for advanced glycation end products
(RAGE) expression (Piras et al., 2014), BACE1 protein levels (Piccini et al.,
2012), and inhibit lysosomal activity, through the activation of the
nuclear factor (NF)-jB pathway (Guglielmotto et al., 2012). Therefore,
Ab oligomers and monomers have completely different pathologic and
physiologic effects (Guglielmotto et al., 2014).
Our experiments show that Ab monomers, but not oligomers, after
3 h of intraventricular injection in mice expressing wild-type human Tau,
change Tau conformation, displaying an epitope present only in
pathological Tau aggregates (Weaver et al., 2000). In the same
experimental conditions, Ab monomers induce two phosphorylated
epitopes not present in normal Tau (Ser396 and Ser422) and activate
GSK3b and MAPK, two kinases responsible for phosphorylation at these
two residues. Indeed, inhibition of the kinases rescues phosphorylation
of Tau. Moreover, inhibition of kinases hampers the conformational
change of Tau determined by Ab monomers.
Then, we asked whether the observed modifications of Tau could
depend on an increase of Tau expression and/or protein levels. The
increase of total Tau leads to higher levels of its protein levels, a
condition that favors phosphorylation and aggregation, as demonstrated
with mutant Tau, when unable to bind tubulin (Holton et al., 2001;
Bunker et al., 2006). We observed that Abmonomers, in parallel with an
increase of Tau protein levels, impair proteasomal degradation. Instead,
Tau mRNA is unchanged. Thus, Ab monomers alter Tau conformation
through two mechanisms: hyperphosphorylation and increase of total
Tau levels. Their relative influence in producing Tau aggregation remains
to be determined. Moreover, the results show that Ab does not have a
direct nucleation effect on Tau.
Fig. 3 Ab1-42 monomers promote phosphorylation at particular sites that have
been related to Alzheimer’s disease (AD) progression. Representative Western blot
of brain extracts (20 lg protein) from control (saline) and treated (Ab1-42 peptides
by ICV for 3 h) mice using antibodies specific for the detection four pathological
Tau phosphorylation sites: AT8, pS396, pS262, and pS422. An antibody raised
against GAPDH or Tau 5 served as loading control. Densitometric quantification
shows an increase of the total protein level of AT8, pS396, and pS422 induced by
monomers while monomeric and oligomeric preparations did not change pS262
expression. The data are mean  standard error of the mean (SEM), *P < 0.05;
***P < 0.001 vs. control by one-way ANOVA followed by Bonferroni post hoc test,
n = 6.
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Ab1-42 oligomers recapitulate all the described alterations of
Tau only after 4 days from the intraventricular injections. At this time,
oligomers have the same electrophoretic pattern of monomers in mice
brains, as shown in Fig. 6C. It is known that Ab monomers,
oligomers, and fibrils are in dynamic balance in AD brains (Nisbet
et al., 2015).
Ab1-42 is certainly implicated in normal neuronal activity. Its
concentration in interstitial fluid is proportional to the level of global
brain function (Fagan et al., 2009). Picomolar concentrations of Ab1-42
foster synaptic activity (Puzzo et al., 2008). Higher Ab1-42 levels have
the opposite effect (Puzzo & Arancio, 2013). It is reasonable to speculate
that low, physiologic, and higher, pathologic, concentrations of Ab1-42
correspond to monomers and oligomers of the peptide, respectively.
With this background, we propose that Ab1-42 has normally the role
of promoting neuronal plasticity, enhancing the levels of Tau and
accelerating the cellular signaling that favors dendritic sprouting. The
exaggeration of these effects, determined by increase of the levels of Ab
monomers, causes Tau aggregation, finally leading to neurofibrillary
pathology.
Our results have practical implications; currently, the major efforts of
Alzheimer’s disease therapy are focused on removal of Ab oligomers,
and not monomers.
Experimental procedures
Mice and ICV
hTau mice (Mapt tm1(EGFP)KltTg(MAPT) 8cPdav/J; #004808, Jackson Lab-
oratory) were crossed with Tau knockout (KO) mice (Mapt tm1(EGFP)Klt/J;
#004779, Jackson Laboratory, Bar Harbor, ME USA), to obtain pregnant
females carrying hTau fetuses as described by Andorfer et al. (2003).Mice
were genotyped by PCR assay using the following primers: human tau
transgene (forward 50-ACTTTGAACCAGGATGGCTGAGCCC-30, reverse
50-CTGTGCATGGCTGTCCCTACCTT-30), mouse tau gene (forward
50-CTCAGCATCCCACCTGTAAC-30, reverse 50-CCAGTTGTGTATGTC
CACCC-30), and disrupted tau gene (forward 50-CAGGCTTTGAACCAG
TATGG-30, reverse 50- TGAACTTGTGGC CGTTTACG-30). Mice were
maintained on a Swiss Webster/129/SvJae/C57BL/6 background (Andor-
fer et al., 2003) (See Fig. S1 in Supporting Information).
Animals were kept on a 12-h light/dark cycle with food and water
available ad libitum. All experimental procedures on live animals were
performed under the supervision of a licensed veterinarian, according
to: (i) European Communities Council Directive (November 24,
1986; 86/609/EEC), (ii) Italian Ministry of Health and University of
Torino’s institutional guidelines on animal welfare (DL 116/92 on Care
Fig. 4 Ab1-42 monomers affect Tau
phosphorylation through GSK3b, ERK1/2,
and JNK kinases activation. Representative
Western blot of brain extracts from control
(saline) and treated mice using pGSK3b (A),
CDK5/p35 (B), pP38, pERK1/2, and pJNK
(C) antibodies for detection. Densitometric
quantification shows an increase in the
total protein level of pGSK3b induced by
monomers (A), while CDK5/p35 was not
modified by any treatments (B). (A,B) An
antibody raised against GAPDH was used as
loading control. The data are
mean  standard error of the mean (SEM),
*P < 0.05 vs. control by one-way ANOVA
followed by Bonferroni post hoc test, n = 6
for each kinase. (C) pP38, pERK1/2, and
pJNK levels were standardized against their
respective total protein amount.
Densitometric quantification shows an
increase of ERK1/2 and JNK activity due to
monomers, while p38 was not involved by
any treatments. The data are
mean  standard error of the mean (SEM),
*P < 0.05; **P < 0.01 vs. control by two-
way ANOVA followed by Bonferroni post
hoc test, n = 3 for each kinase.
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and Protection of living animals undergoing experimental or other
scientific procedures; authorization No. 17/2010-B, June 30,
2010), and (iii) ad hoc Ethical Committee of the University of Turin
(http://www.unito.it/ricerca/strutture-la-ricerca/comitato-di-bioetica-dell
ateneo).
Two groups of 2-month-old male mice were used: (i) treated for 3 h
(n = 60) and (ii) treated for 4 days (n = 25). Under isoflurane O2/N2O
anesthesia, hTau mice (n = 100) were ICV injected with Ab peptides or
saline. Coordinates used for injection were anteroposterior, 0.5 mm;
lateral, 1.2 mm relative to bregma and dorsoventral, 1.7 mm from the
dural surface. The method was validated by injecting one mouse with
trypan blue (1 lL).
Treatments
Mice were injected with 0.2 lM Ab1-42 peptides (#20276, Anaspec).
The lyophilized synthetic peptides were dissolved in 1.0% of NH4OH to
obtain a clear solution and stored at 20 °C in aliquots. Monomeric
preparations were brought to 0.2 lM (final concentration) with sterile
double-distilled water, centrifuged at 10 000 g for 10 min to remove
possibly aggregate and immediately added to the cell culture. Oligomeric
preparations were maintained at 4 °C for 24 h and then injected.
The quality of Ab preparations was controlled using AFM. AFM was
carried out on a Multimode AFM with a Nanoscope V system operating
in tapping mode using standard antimony(n)-doped Si probes (T: 3.5–
4.5 mm, L: 115–135 mm, W: 30–40 mm, f0: 313–370 kHz, k: 20–
80 N m1) (Bruker). The scan rate was tuned proportionally to the area
scanned and was kept in the 0.5–1.2 Hz range. The sample was then
diluted to 5 lM with PBS, and 50 lL of solution was spotted onto a
freshly cleaved muscovite mica disk and incubated for 5 min. The disk
was then washed with ddH2O and dried under a gentle nitrogen stream.
Samples were analyzed with the SPIP (version 5.1.6 released April 13,
2011) data analysis package (Nanoscience Instruments, Phoenix, AZ,
USA). SPIP software was used to analyze the distribution of the molecular
assemblies of the different populations in terms of height and diameter,
as previously described (Messa et al., 2014).
DEPSI-Ab1–42 peptide was synthesized using depsipeptide method as
previously described (Beeg et al., 2011; Stravalaci et al., 2011). Ab1–
42WT was stored in water: trifluoroacetic acid, 0.02% at a concentra-
tion of 150 lM. The depsipeptide method, through the introduction of
O-acyl isopeptide structure into the Gly-25–Ser-26 sequence stable at
acidic pH, is able to inhibit the self-aggregation of the peptide. Upon a
change to basic pH (switching procedure), the depsipeptide is converted
to the Ab1–42 native sequence.
After the switching, Ab1–42 solution was brought to a final
concentration of 100 lM in 50 mM phosphate buffer, pH 7.4, and
incubated for 24 h at 4 °C to obtain the oligomer rich solution (Beeg
et al., 2011; Stravalaci et al., 2011).
Fig. 5 After 4 days of treatment, Ab1-42
oligomers and the monomers show a
similar effect on Tau protein and phospho-
kinases. Representative Western blot of
brain extracts from control (saline) and
treated mice using MC1 and Tau5 (A),
pERK1/2, pJNK, and pGSK3b (B) antibodies
for detection. (A) Densitometric
quantification shows an increase in the
total protein level of both MC1 and Tau5
induced by both preparations. An antibody
raised against GAPDH served as loading
control. The data are mean  standard
error of the mean (SEM), *P < 0.05,
**P < 0.01 vs. control by one-way ANOVA
followed by Bonferroni post hoc test,
n = 3. (B) Densitometric quantification
shows an increase of ERK1/2 and JNK
activity due to both monomers and
oligomers treatments. pERK1/2 and pJNK
levels were standardized against their
respective total protein amount. The data
are mean  SEM, **P < 0.01 vs. control by
two-way ANOVA followed by Bonferroni
post hoc test, n = 3 for each kinase. (C)
Representative Western blot of the
aggregation state of Ab1-42 in brain tissue
of hTau mice injected after 3 h or 4 days
with both preparations using the 6E10
antibody. As shown, the aggregation state
of oligomeric preparation was different in
the short and in the longer treatment: After
3 h, a band of approximately 12 Kda was
observed, whereas after 4 days, this band
was no more detectable. The data are
mean  SEM, **P < 0.01 vs. control by
two-way ANOVA followed by Bonferroni
post hoc test, n = 3.
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The number of mice/group was determined with a standard power
analysis (Faul et al., 2007). We set the significance level (probability of a
type-I error) at 5% (a = 0.05) and chose a sample size that would
minimize the probability of type-II errors (b ≤ 10%). From our initial
experiment, we obtained estimates of the expected effects of the 3 h
ICV treatment, and variability for a given number of mice determining
that a sample size of nine animals in each treatment group would be
sufficient to detect a 30% difference in immunoreactivities (described
below) with a statistical power of 95%. Our controls were hTau mice ICV
injected with saline or with Ab1-42 scramble (Anaspec S-25382).
Intraventricularly, injection of hTau mice with scramble peptide did not
modify the conformational change on Tau with respect to saline control
(see Fig. S2 in Supporting Information). To investigate whether c-Jun N-
terminal kinase (JNK), extracellular signal regulated MAP kinase (ERK)1/2,
and glycogen synthase kinase (GSK)3b are involved in Ab1-42-induced
conformational change of Tau, we used three different groups of 2-
month-old animals killed 3 h after the Ab1-42 injection, one for
inhibitor. The peptides JNK inhibitor SP600125 (5 lg lL1) (#20276;
Santa Cruz Biotechnology, Dallas, Texas, USA) and ERK inhibitor
PD98059 (0.1 mg mL1) (#20276, Santa Cruz Biotechnology) were
injected ICV 30 min before Ab1-42 injection. The peptide GSK3 inhibitor
AZD1080 (1 lM mL1, #S7145; Selleckchem, Houston, TX, USA) was
given via oral gavage 6 h before Ab1-42 injection.
Antibodies and immunoblot analysis
Immunoblot analysis was performed using the following antibodies:
MC1 (kind gift from Dr. P Davies, Albert Einstein College of Medicine,
New York, 1:500); Tau5 (Millipore, #577801, 1:500); AT8 (Innogenetics,
Alpharetta, GA, USA, #90206, 1:500); Tau 46 (Abcam, Cambridge, UK,
#22261, 1:1000), Tau RD4 (Millipore, Billerica, MA, USA, #05-804,
1:1000), Tau RD3 (Millipore #05-803, 1:1000), TaupS396 (Invitrogen,
#44752G, 1:1000); TaupS262 (Invitrogen, #44750G, 1:1000); TaupS244
(Invitrogen, Camerillo, CA, USA, #44764G, 1:1000); GSK3apY279/
bpY216 (Invitrogen, #44604G, 1:1000); GSK3a/b tot (1:1000, Invitro-
gen, #44610, 1:1000); GSK3bpS9 (Novex, Frederick, MD, USA,
#710100, 1:1000); pJNK1/2 (Cell Signaling Technology, Beverly, MA,
USA, #9251, 1:500); JNK1/2 (Cell Signaling Technology, #9252, 1:500);
pP38 (Calbiochem, #506119, 1:1000); P38 (Calbiochem, San Diego, CA,
USA, #06123, 1:1000); pERK1/2 (Cell Signaling Technology, #43765,
1:1000); ERK1/2 (Santa Cruz Biotechnology, Dallas, Texas, USA, Sc-93,
1:1000); 6E10 (Chemicon, Billerica, MA, USA, Mab1560, 1:500);
Fig. 6 The activation of JNK, ERK1/2, and
GSK is required to mediate the
conformational change of Tau protein
induced by Ab1-42 monomers.
Representative Western blot of brain
extracts from control and pretreated or not
with the GSK3b inhibitor AZD1080, ERK
inhibitor PD98059, and JNK inhibitor
SP600125 before 3 h injection with Ab1-42
Tau mice using MC1 (A-C), pGSK3b (A),
pJNK (B), and pERK1/2 (C) antibodies for
detection. An antibody raised against
GAPDH or Tau5 served as loading control.
Densitometric quantification shows that
each pretreatment was followed by a
complete inhibition of the pathway and by
the complete reversion of Tau
conformational change (A–C). The data are
mean  standard error of the mean (SEM),
**P < 0.01 vs. control by one-way ANOVA
followed by Bonferroni post hoc test, n = 6
for each kinase.
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glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Millipore,
Mab374, 1:3000).
Fresh frozen brains were mechanically homogenized in ice-cold buffer
(25 mM Tris-HCl pH7.4, 150 mM NaCl, 1 mM EGTA, 1 mM EDTA, 1 mM
PMSF, phosphatase, and protease inhibitors) and then centrifuged at
10 000 g for 15 min al 4 °C to isolate soluble proteins. Supernatants
(2 mg mL1 solution) were collected and incubated with sarkosyl (1%
final concentration) overnight at 4 °C. The sarkosyl mixtures were then
centrifuged in Beckman SW 55 Ti rotor, Brea, CA, USA, at 116140 g for
1 h at 4 °C. Pellets were resuspended in 100 lL sample buffer to obtain
sarkosyl-insoluble proteins. Lysates (20 lg) were run on 3–8% Tris-HCl
gradient PAGE gel (Invitrogen) and then transferred to PVDF membrane.
To determine the presence of Ab1–42 oligomers in brain tissues, lysates
were separated on 10–17.5% Tris–tricine gels, transferred onto nitro-
cellulose membranes. Blots were blocked (5% BSA) and incubated
overnight at 4 °C with primary antibodies. Peroxidase-conjugated
secondary antibodies were incubated 1 h at room temperature (RT)
and developed with Luminata Forte Western substrate (WBLUF0100,
Millipore). Densitometric values were normalized to GAPDH.
Immunofluorescence and microscopy
Brains were removed and cryoprotected in 30% sucrose after trans-
cardiac perfusion with 4% paraformaldehyde. Samples were cut into
coronal free-floating sections (25 lm). For immunofluorescence stain-
ing, sections were blocked and incubated overnight at 4 °C with AT8
(Thermo Fisher Scientific, Carlsbad, CA, USA, #MN1020, 1:25). Cy3-
conjugated secondary antibody (Jackson Immuno Research Laborato-
ries, West Grove, PA, USA, 715-165-150, 1:200) was incubated 1 h at
RT, and DAPI (Sigma Chemical Aldrich, Milwaukee, WI, USA) was used
to stain nuclei. Controls included: Tau KO brains stained with AT8, and
sections treated with secondary antibody alone. Neither showed
appreciable staining. Images were acquired using Leica TCS SP5
confocal laser scanning microscopes (Leica, Richmond, IL, USA). The
percentage of the overall AT8-positive cells in the CA1 areas of
hippocampus was quantified using the IMAGEJ NIH software for Windows
(Bethesda, MA, USA).
RNA extraction and quantitative real-time PCR
Three hours after ICV injection, brain of 2-month-old male mice were
homogenized in TRI-Reagent (Sigma Chemical Aldrich) and total RNA
was isolated. cDNA was synthesized using the M-MLV Reverse
Transcriptase (Invitrogen) and random primers. qPCR was performed
using the qPCR Core kit for SYBR Green (Eurogentec, San Diego, CA,
USA) on a StepOne real-time PCR system (Life Technologies, Carlsbad,
CA, USA). Samples were amplified simultaneously in triplicate in 1 assay
run. Changes in mRNA levels were determined as the difference in
threshold cycle (DCt) between the target gene and the reference gene.
The following primers were used: 50-TGAACCAGGATGGCTGAGC-30
and 50-TTGTCATCGCTTCCAGTGC-30 for Tau exon2, 50-CCACCAACT
GCTTAGCCCCC-30 and 50-GCAGTGATGGCATGGACTGTGG-30 for
GADPH (internal standard).
Proteasome activity assay
The proteasome activity assay was determined using a commercially
available kit (Chemicon). The assay is based on detection of the
fluorophore 7-amino-4-methylcoumarin after cleavage from the labeled
substrate LLVY-AMC. The free AMC fluorescence can be quantified
using a 380/460 nm filter set in a fluorometer.
Statistical analysis
Statistical analyses were performed using GRAPHPAD PRISM version 4.0
(GraphPad Software, San Diego, CA, USA). All values were presented as
mean  standard error of the mean. Means were compared by one- or
two-way analysis of variance (ANOVA) with Bonferroni as a post hoc
test. Values of *P < 0.05 were considered significant, **P < 0.01 very
significant and ***P < 0.001 extremely significant.
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Fig. S1 (A) Breeding scheme from mating hTau mice (Mapt tm1(EGFP)KltTg
(MAPT) 8cPdav/J; #004808, Jackson Laboratory); murine (m) Tau knock-out
(KO) mice (Mapt tm1(EGFP)Klt/J; #004779, Jackson Laboratory) to generate
hTau + mTauKO mice. (B, C) Specific PCR analysis of genomic DNA. Note: (B)
transgene (tg) = 187 bp. (c) Mutant (KO) = 490 bp. 1Kb DNA ledder was
used in both analysis
Fig. S2 Representative western-blot of brain extracts from control (saline)
and mice injected with Ab 1-42 scramble preparation using MC1 (A) antibody
for detection. Densitometric quantification did not reveal changes in the total
protein level of MC1 induced by both treatments. An antibody raised against
GAPDH served as loading control. n = 3 for each treatments.
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